BEIJING, Oct. 30, 2025 — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focused on developing treatments for cancer and autoimmune diseases, today announced the first patient has been dosed in China in the clinical trial for ICP-B794, its novel B7-H3 targeted antibody-drug conjugate (ADC).
ICP-B794 is a novel ADC that combines a humanized anti-B7-H3 monoclonal antibody with a potent, internally developed payload via a protease-cleavable linker. This design allows for precise targeting of tumor cells, reducing off-target effects and presenting a promising treatment option for various solid tumors, including lung, esophageal, nasopharyngeal, head and neck squamous cell carcinomas, and prostate cancers. In animal models, ICP-B794 has shown superior anti-tumor activity compared to other ADCs and has demonstrated significant tumor-killing effects, even in large tumors.
Currently, there are no approved B7-H3 targeted therapies available worldwide. B7-H3, a type I transmembrane protein, is highly expressed in many solid tumor types. Its tumor-specific expression makes it a highly attractive anti-tumor target.
Dr. Jasmine Cui, co-founder, chairwoman, and CEO of InnoCare, stated that B7-H3 is highly expressed in a variety of solid tumors. She added that ICP-B794, developed using their proprietary ADC platform and its unique design, has the potential to deliver precise treatment options for cancer patients. Dr. Cui also mentioned their continued commitment to expanding their portfolio with multiple ADC candidates to bring more hope to cancer patients globally.
InnoCare’s ADC platform is designed to target difficult-to-treat cancers. The company’s innovative platform technology aims to achieve stronger tumor-killing effects and an improved safety profile when developing new ADC drugs, ultimately providing better treatment options for cancer patients worldwide.
About InnoCare
InnoCare is a commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for cancers and autoimmune diseases with unmet medical needs in China and around the world. InnoCare has locations in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report includes forward-looking statements. All statements, except for statements of fact, can be considered forward-looking statements, including those about our or our management’s intentions, plans, beliefs, or expectations regarding future events. These statements are based on assumptions and estimates made by our management, drawing on their experience and understanding of historical trends, current conditions, anticipated future developments, and other relevant factors. These forward-looking statements do not guarantee future performance, and actual results, development, and business decisions may differ from the expectations expressed in the forward-looking statements. Our forward-looking statements are subject to numerous risks and uncertainties that may impact our short-term and long-term performance.
| Media | Investors |
| Chunhua Lu | |
| 86-10-66609879 | 86-10-66609999 |
